trial

Bexarotene Treatment in Schizophrenia

NCTId NCT00141947
as of 2026-07-01
Add to landscapeMonitor thisAsk about this
at a glance
Phase 3 · Unknown
Enrollment 15 (estimated)
Sponsored by Beersheva Mental Health Center
Synthesized from structured facts only — each point cited above.

Design & status

Phase
Phase 3
Status
Unknown
Enrollment
15 (estimated)
Study type
Interventional
Allocation
Non Randomized
Model
Single Group
Masking
None
Start
2005-09
Primary completion
—
Eligibility
ALL · 18 Years · 60 Years

Interventions & indications

Drugs
bexarotene (Targretin)

Sponsors

Beersheva Mental Health CenterLead Sponsor
Stanley Medical Research InstituteCollaborator

Investigators

2
Prof. Vladimir Lerner, MD, PhDPrincipal Investigator
Michael S. Ritsner, MD, PhDPrincipal Investigator

Sites

2 total
Beersheva, IsraelHadera, Israel

Facts & assertions

3 sourced
Enrollment
15
Phase
PHASE3
Status
UNKNOWN
relationships
The graph out of here
drug
bexarotene (Targretin)
drug
lead_sponsor
Beersheva Mental Health Center
company
collaborator
Stanley Medical Research Institute
company
indication
Schizophrenia
indication
Schizophrenia
indication
Cognitive Dysfunction
indication
investigator
Prof. Vladimir Lerner, MD, PhD
person
Michael S. Ritsner, MD, PhD
person